Prediction of 10yr distant recurrence (DR) using the Prosigna® (PAM50) assay in histological subgroups of a DBCG cohort of postmenopausal Danish women with hormone receptor-positive (HR+) early breast cancer (EBC) allocated to 5yr of endocrine therapy (ET) alone

Anne-Vibeke Lænkholm¹, Maj-Britt Jensen², Jens Ole Eriksen¹, Torben Kibøl¹, Birgitte Bruun Rasmussen³, Ann S. Knoop⁴, Wesley Buckingham⁵, Sean Ferree⁵, Taryn Haffner⁵, Carl Schaper⁵, Bent Ejlertsen²,⁴

1. Department of Pathology, Region Zealand
2. The Danish Breast Cancer Cooperative Group, DBCG Secretariat, Rigshospitalet
3. Department of Pathology, Herlev Hospital
4. Department of Oncology, Rigshospitalet